Search Results
Apr 14, 2026, 03:00 ET ARTHEx Biotech Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
enhanced tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional
More news about: ARTHEx Biotech
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
is a first-in-class antibody-drug conjugate (ADC) comprising a folate receptor alpha-binding antibody, cleavable linker and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. ELAHERE® is currently indicated for the treatment of adult patients
More news about: AbbVie
Apr 10, 2026, 07:25 ET DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt
durchgeführt wird. Ziel der Studie ist die Bewertung der Wirksamkeit und Sicherheit von Trastuzumab Pamirtecan im Vergleich mit Trastuzumab Emtansin (T-DM1) bei Patienten mit HER2-positivem, nicht resezierbarem oder metastasiertem Brustkrebs, die zuvor Trastuzumab und eine Taxan-Chemotherapie erhalten hatten.
More news about: DualityBio
Apr 10, 2026, 07:23 ET DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte
ouvert et multicentrique mené en Chine. Il vise à évaluer l'efficacité et la sécurité du trastuzumab pamirtecan par rapport au trastuzumab emtansine (T-DM1) chez les patientes atteintes d'un cancer du sein HER2 positif non résécable ou métastatique ayant déjà reçu une chimiothérapie à base de trastuzumab
More news about: DualityBio
Apr 09, 2026, 12:55 ET DualityBio anuncia la aceptación de NMPA de China de su solicitud de licencia para productos biológicos
fase III realizado en China. El objetivo es evaluar la eficacia y la seguridad de trastuzumab pamirtecan en comparación con trastuzumab emtansina (T-DM1) en pacientes con cáncer de mama HER2-positivo irresecable o metastásico que hayan recibido previamente quimioterapia con trastuzumab y taxanos. Según
More news about: DualityBio
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Apr 09, 2026, 09:00 ET Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
advanced into the critical Phase III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). Existing clinical data demonstrate that Bofanglutide can effectively reduce body weight and blood glucose levels
More news about: Gan & Lee Pharmaceuticals
Apr 09, 2026, 08:16 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed
More news about: DualityBio
Apr 09, 2026, 07:55 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed
More news about: DualityBio
Apr 07, 2026, 09:00 ET Halcyon Appoints Dave Hannigan as Field Chief Information Security Officer
Dave Hannigan, Field CISO, Halcyon.Hannigan also serves as an independent board member for Zero Hash Trust and as a security advisor for Fleet DM. He is a former startup founder and active mentor within the cybersecurity community, with a focus on helping organizations use security as a driver of
More news about: Halcyon
Apr 06, 2026, 10:00 ET K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 45 DM1 molecules per antibody, significantly higher than
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Новый унимицеллярный конъюгат, загруженный антителом и лекарственным средством, демонстрирует опухолеселективную фармакокинетику, обширное внутриопухолевое распределение и превосходную эффективность в доклинических моделях на животных
загруженными лекарственным препаратом (DM1), которые содержат значительное количество полезных нагрузок в одноцепочечном полимере. Этот инновационный подход позволяет получить сверхвысокое DAR (отношение лекарственного препарата к антителу), составляющее приблизительно 45 молекул DM1 на одно антитело, что значительно
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: nový konjugát unimicelov s obsahom protilátok a liečiv vykazuje selektívnu farmakokinetiku pre nádory, rozsiahlu intratumorálnu distribúciu a vynikajúcu účinnosť v neklinických zvieracích modeloch.
protilátku proti EGFR s unimicelami s obsahom liečiva (DM1), ktoré do jednoreťazcového polyméru začleňujú značné množstvo užitočného zaťaženia. Tento inovatívny prístup dosahuje ultravysoký pomer liečiva k protilátke (DAR), približne 45 molekúl DM1 na protilátku, čo je výrazne viac ako pri konvenčných
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Ein neuartiges, mit Antikörpern beladenes Unimicelle-Konjugat zeigt Tumor-selektive Pharmakokinetik, weitreichende intratumorale Verteilung und überlegene Wirksamkeit in nicht-klinischen Tiermodellen
Anti-EGFR-Antikörper mit arzneimittelbeladenen Unimicellen (DM1), die erhebliche Mengen von Nutzlasten in ein einkettiges Polymer einbauen. Mit diesem innovativen Ansatz wird ein extrem hohes DAR-Verhältnis (Drug-to-Antibody Ratio) von etwa 45 DM1-Molekülen pro Antikörper erreicht, was deutlich höher ist
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Nový konjugát unimicely nesoucí protilátku a léčivo vykazuje nádorově selektivní farmakokinetiku, rozsáhlou intratumorální distribuci a vynikající účinnost v neklinických zvířecích modelech
anti-EGFR protilátku s unimicelami nesoucími léčivo (DM1), které do jediného polymerního řetězce začleňují značné množství užitečného zatížení. Tento inovativní přístup dosahuje ultra vysokého poměru léčiva k protilátce (DAR) přibližně 45 molekul DM1 na jednu protilátku, což je výrazně více než u konvenčních
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 45 DM1 molecules per antibody, significantly higher than
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: innowacyjny koniugat przeciwciała i miceli będącej nośnikiem leku wykazuje właściwości farmakokinetyczne umożliwiające selektywne oddziaływanie na guzy nowotworowe, rozległe działanie wewnątrz guza i wysoką skuteczność w nieklinicznych modelach zwierzęcych
przeciwciała anty-EGFR z micelą będącą nośnikiem leku (DM1), mieszcząc znaczne ilości substancji w polimerze prostym. Dzięki temu innowacyjnemu podejściu uzyskano ultrawysoki stosunek leku do przeciwciała (DAR, Drug-to-Antibody Ratio) na poziomie ok. 40 cząsteczek DM1 na przeciwciało, znacznie wyższym niż w przypadku
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Un nouveau conjugué d'anticorps chargé de Unimicelle présente une pharmacocinétique sélective de la tumeur , une distribution intratumorale étendue et une efficacité supérieure dans les modèles animaux non cliniques.
des unimicelles chargées de médicaments (DM1), qui incorporent des quantités substantielles de charges utiles dans un polymère à chaîne unique. Cette approche innovante permet d'obtenir un ratio DAR (Drug-to-Antibody Ratio) très élevé d'environ 45 molécules de DM1 par anticorps, ce qui est nettement supérieur
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET El conjugado K-679 demuestra farmacocinética selectiva para tumores
anti-EGFR con unimicelas cargadas con fármaco (DM1), que incorporan cantidades sustanciales de carga útil en un polímero de cadena única. Este enfoque innovador logra una relación fármaco-anticuerpo (DAR) ultra alta de aproximadamente 45 moléculas de DM1 por anticuerpo, significativamente superior a
More news about: Kowa Company Ltd.
Apr 02, 2026, 21:44 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Apr 01, 2026, 09:00 ET From Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist
type 2 diabetes mellitus (T2DM), representing only the initial phase of its commercial lifecycle. A substantially larger opportunity lies ahead: the obesity indication—a therapeutic area with a total addressable market estimated to be approximately tenfold greater than that of T2DM in China. A
More news about: Innogen
Mar 31, 2026, 09:36 ET Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
insulin-naïve adults with T2DM, comparing the efficacy and safety of once-weekly GZR4 Injection versus once-daily insulin glargine U100 (Lantus®), both in combination with non-insulin anti-diabetic treatment.SUPER-2: A 26-week trial enrolling 631 adults with T2DM previously treated
More news about: Gan & Lee Pharmaceuticals
Mar 30, 2026, 06:45 ET Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System
SS, Jung HU. Pathophysiological aspects of ureterorenoscopic management of upper urinary tract calculi. Curr Opin Urol.2016;26:63–69Schwalb DM, Eshghi M, Davidian M, et al. Morphological and physiological changes in the urinary tract associated with ureteral dilation and ureteropyeloscopy: an
More news about: Boston Scientific Corporation
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades:
More news about: Amgen